<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <meta name="author" content="Michael N. Zietz" />
  <meta name="date" content="2017-08-15" />
  <meta name="keywords" content="work-in-progress, markdown, manuscript, publishing" />
  <title>Vagelos Report Summer 2017</title>
  <style type="text/css">code{white-space: pre;}</style>
  <link rel="stylesheet" href="github-pandoc.css" type="text/css" />
  <script src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS_CHTML-full" type="text/javascript"></script>
  <!-- Insert Analytics Script Below -->
  <script>
  </script>
  <!-- End Analytics Script -->
</head>
<body>
<div id="header">
<h1 class="title">Vagelos Report Summer 2017</h1>
</div>
<p><small><em> This manuscript was automatically generated from <a href="https://github.com/zietzm/Vagelos2017/tree/a5883a02df549a58a9ef6ec06ad8815e933835ca">zietzm/Vagelos2017@a5883a0</a> on August 15, 2017. </em></small></p>
<h2 id="authors">Authors</h2>
<ul>
<li><strong>Michael N. Zietz</strong><br> · <img src="images/github.svg" alt="GitHub icon" height="13" /> <a href="https://github.com/zietzm">zietzm</a><br> <small> Greene Lab, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania </small></li>
</ul>
<h2 id="scientific-background">Scientific background</h2>
<h3 id="drug-development">Drug development</h3>
<p>Drug development times and R&amp;D expenditures have risen considerably in the last decades. In fact, to bring a new compound to market can take a 14 years on average <span class="citation">[<a href="#ref-LlRXV6lE">1</a>]</span>. This development process, according to a 2016 estimate by DiMasi et al. <span class="citation">[<a href="#ref-13c9OPizf">2</a>]</span>, costs an average of $2.87 billion dollars, including post-approval R&amp;D. This amount is up from two previous studies by the same authors which found the average captialized R&amp;D costs to be $802 million in 2003 <span class="citation">[<a href="#ref-nn9rnuHx">3</a>]</span> and $318 million in 1991 <span class="citation">[<a href="#ref-269zMv7S">4</a>]</span>. Despite increases in drug development time and expenditures, the rate of R&amp;D failure has increased since the 1990s <span class="citation">[<a href="#ref-z38InjRh">5</a>]</span>. Only about one in 5,000 compounds which begin preclinical testing are eventually approved <span class="citation">[<a href="#ref-g5JcTYOY">6</a>]</span>. Even among those which enter phase I of clinical development, only an estimated one in ten drugs will receive FDA approval <span class="citation">[<a href="#ref-o8yROPbx">7</a>]</span>.</p>
<h3 id="drug-repurposing">Drug repurposing</h3>
<p>Drug repurposing refers to the application of an existing therapeutic to a different disease than the one for which it was originally intended. Because candidates for drug repurposing have already been approved for other diseases, the time and cost associated with repurposing a drug are very small compared to the development of a new drug <span class="citation">[<a href="#ref-c7z5BwrM">8</a>]</span>. In fact, even compounds which have been deemed safe but failed in clinical development for other reasons can be candidates for drug repurposing. Several examples exist of drugs which have been repurposed, for example aspirin to treat coronary artery disease, sildenafil to treat erectile dysfunction, and gabapentin to treat postherpetic neuralgia. Most successfully repurposed drugs were discovered serendipitously and not through any systematic discovery mechanism. Our goal is to make accurate predictions of drugs which are candidates for drug repurposing. We hope to do this using heterogeneous networks of biomedical information to learn the patterns of connections between compounds and diseases.</p>
<h2 id="summer-aims">Summer aims</h2>
<p>This summer I worked within the Greene Lab project called ‘Hetmech’ <span class="citation">[<a href="#ref-X1hJHTyw">9</a>]</span>. Hetmech aims to improve upon and expand the existing method for predicting drug repurposing targets.</p>
<p>I had three primary aims for my work this summer. The details of all are covered in the Methods section.</p>
<p>First, I wanted to add capability within Hetmech to compute the degree-weighted path count (DWPC). Previously, the two options had been an inaccurate DWPC method and a degree-weighted walk count (DWWC), whose limitations will be covered in the Methods section.</p>
<p>Second, I hoped to decrease the time required to make calculations of DWPC. Towards this aim, I hoped to speed up computation by at least an order of magnitude. Sparse matrices and parallel computation were planned solutions to this problem.</p>
<p>Finally, it was my goal to add a multiple search capability. This involves querying a set of nodes to return a set of predictions for nodes which connect the queried nodes. For example, one should be able to search a set of symptoms and return a list of potential diseases that connect the symptoms. As with the previous problems, moving to strictly matrix computation makes this much more simple.</p>
<h2 id="methods">Methods</h2>
<h3 id="heterogeneous-networks">Heterogeneous networks</h3>
<p>Heterogeneous networks (‘hetnets’) are networks with multiple node types and edge types. In the network used this summer, titled Hetionet v1.0 (Figure <a href="#fig:metagraph">1</a> B), nodes represent instances of 11 biomedical entity types, and edges correspond to one of 24 edge types, or relationships between entities. ‘Graph’ in this context refers to the entire network of nodes and edges. We define ‘metagraph’ to mean a graph of the types of nodes and edges in Hetionet (Figure <a href="#fig:metagraph">1</a> A).</p>
<div class="figure">
<img src="https://raw.githubusercontent.com/zietzm/Vagelos2017/master/content/images/graph_metagraph.png" alt="Figure 1: A. Metagraph. The graph of metandoes (node types) and metaedges (edge) type. B. Graph (Hetionet v1.0) The circles and lines represent nodes within the labeled types. For example, within the metanode Anatomy we could have the node Leukocyte." id="fig:metagraph" />
<p class="caption">Figure 1: A. Metagraph. The graph of metandoes (node types) and metaedges (edge) type. B. Graph (Hetionet v1.0) The circles and lines represent nodes within the labeled types. For example, within the metanode ‘Anatomy’ we could have the node ‘Leukocyte’.</p>
</div>
<p>Hetionet v1.0 incorporated 47,031 nodes and 2,250,197 edges <span class="citation">[<a href="#ref-XJuQlZl1">10</a>]</span>. A further breakdown of the nodes and edges can be found below in Tables <a href="#tbl:nodes-by-type">1</a> and <a href="#tbl:nodes-by-source">2</a>, respectively.</p>
<a name="tbl:nodes-by-type"></a>
<table>
<caption>Table 1: Breakdown of nodes by type </caption>
<thead>
<tr class="header">
<th>Metanode</th>
<th>Nodes</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Anatomy</td>
<td>402</td>
</tr>
<tr class="even">
<td>Biological Process</td>
<td>11,381</td>
</tr>
<tr class="odd">
<td>Cellular Component</td>
<td>1,391</td>
</tr>
<tr class="even">
<td>Compound</td>
<td>1,552</td>
</tr>
<tr class="odd">
<td>Disease</td>
<td>137</td>
</tr>
<tr class="even">
<td>Gene</td>
<td>20,945</td>
</tr>
<tr class="odd">
<td>Molecular Function</td>
<td>2,884</td>
</tr>
<tr class="even">
<td>Pathway</td>
<td>1,822</td>
</tr>
<tr class="odd">
<td>Pharmacologic Class</td>
<td>345</td>
</tr>
<tr class="even">
<td>Side Effect</td>
<td>5,734</td>
</tr>
<tr class="odd">
<td>Symptom</td>
<td>438</td>
</tr>
</tbody>
</table>
<a name="tbl:nodes-by-source"></a>
<table>
<caption>Table 2: Breakdown of edges by type and data source </caption>
<thead>
<tr class="header">
<th>Metaedge</th>
<th>Edges</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Anatomy-downregulates-Gene</td>
<td>102,240</td>
<td>Bgee</td>
</tr>
<tr class="even">
<td>Anatomy-expresses-Gene</td>
<td>526,407</td>
<td>Bgee and TISSUES</td>
</tr>
<tr class="odd">
<td>Anatomy-upregulates-Gene</td>
<td>97,848</td>
<td>Bgee</td>
</tr>
<tr class="even">
<td>Compound-binds-Gene</td>
<td>11,571</td>
<td>BindingDB, DrugBank, DrugCentral</td>
</tr>
<tr class="odd">
<td>Compound-causes-Side Effect</td>
<td>138,944</td>
<td>SIDER</td>
</tr>
<tr class="even">
<td>Compound-downregulates-Gene</td>
<td>21,102</td>
<td>LINCS L1000</td>
</tr>
<tr class="odd">
<td>Compound-palliates-Disease</td>
<td>390</td>
<td>PharmacotherapyDB</td>
</tr>
<tr class="even">
<td>Compound-resembles-Compound</td>
<td>6,486</td>
<td>Dice coefficient = 0.5</td>
</tr>
<tr class="odd">
<td>Compound-treats-Disease</td>
<td>755</td>
<td>PharmacotherapyDB</td>
</tr>
<tr class="even">
<td>Compound-upregulates-Gene</td>
<td>18,756</td>
<td>LINCS L1000</td>
</tr>
<tr class="odd">
<td>Disease-associates-Gene</td>
<td>12,623</td>
<td>GWAS Catalog, DISEASES, DisGeNET, DOAF</td>
</tr>
<tr class="even">
<td>Disease-downregulates-Gene</td>
<td>7,623</td>
<td>STARGEO</td>
</tr>
<tr class="odd">
<td>Disease-localizes-Anatomy</td>
<td>3,602</td>
<td>MEDLINE</td>
</tr>
<tr class="even">
<td>Disease-presents-Symptom</td>
<td>3,357</td>
<td>MEDLINE</td>
</tr>
<tr class="odd">
<td>Disease-resembles-Disease</td>
<td>543</td>
<td>MEDLINE</td>
</tr>
<tr class="even">
<td>Disease-upregulates-Gene</td>
<td>7,731</td>
<td>STARGEO</td>
</tr>
<tr class="odd">
<td>Gene-covaries-Gene</td>
<td>61,690</td>
<td>Evolutionary rate covariation = 0.75</td>
</tr>
<tr class="even">
<td>Gene-interacts-Gene</td>
<td>147,164</td>
<td>Evolutionary rate covariation = 0.75</td>
</tr>
<tr class="odd">
<td>Gene-participates-Biological Process</td>
<td>559,504</td>
<td>Gene Ontology</td>
</tr>
<tr class="even">
<td>Gene-participates-Cellular Component</td>
<td>73,566</td>
<td>Gene Ontology</td>
</tr>
<tr class="odd">
<td>Gene-participates-Molecular Function</td>
<td>97,222</td>
<td>Gene Ontology</td>
</tr>
<tr class="even">
<td>Gene-participates-Pathway</td>
<td>84,372</td>
<td>Gene Ontology</td>
</tr>
<tr class="odd">
<td>Gene-regulates-Gene</td>
<td>265,672</td>
<td>Gene Ontology</td>
</tr>
<tr class="even">
<td>Pharmacologic Class-includes-Compound</td>
<td>1,029</td>
<td>DrugCentral</td>
</tr>
</tbody>
</table>
<h3 id="graph-analysis">Graph analysis</h3>
<p>An adjacency matrix refers to a labeled matrix with 1 or 0 at every position, corresponding to the presence or absence of a connection between two nodes <span class="citation">[<a href="#ref-w4Mi034s">11</a>]</span>. The matrix is labeled, meaning that each row and column correspond to a source and target node, respectively. A function was created, titled <code>metaedge_to_adjacency_matrix</code> which performed the conversion from a string metaedge, such as ‘DaG’, to an adjacency matrix.</p>
<div class="figure">
<img src="images/graph.svg" alt="Figure 2: An example graph. Blue nodes are genes, while green nodes are diseases. The edge type between all the nodes in this graph is DaG or Disease-associates-Gene." id="fig:eg_graph" width="480" />
<p class="caption">Figure 2: An example graph. Blue nodes are genes, while green nodes are diseases. The edge type between all the nodes in this graph is ‘DaG’ or ‘Disease-associates-Gene’.</p>
</div>
<p>For example, the graph in Figure <a href="#fig:eg_graph">2</a> has the following adjacency matrix corresponding to ‘GaD’:</p>
<p><span class="math display">\[
\begin{equation}
\begin{bmatrix}
1 &amp; 1 &amp; 0 &amp; 1 &amp; 1 &amp; 1 &amp; 0 &amp; 1 &amp; 0\\
0 &amp; 0 &amp; 1 &amp; 1 &amp; 0 &amp; 0 &amp; 1 &amp; 0 &amp; 0\\
0 &amp; 0 &amp; 0 &amp; 1 &amp; 0 &amp; 0 &amp; 0 &amp; 1 &amp; 1
\end{bmatrix}
\end{equation}
\]</span></p>
<p>with labels for rows and columns, respectively:</p>
<span class="math display">\[\begin{bmatrix}
\textrm{NF2}\\
\textrm{NRXN2}\\
\textrm{SMARCE1}
\end{bmatrix}\]</span>
<span class="math display">\[\begin{bmatrix}
\textrm{epilepsy syndrome}\\
\textrm{kidney cancer}\\
\textrm{pancreatic cancer}\\
\textrm{spinal cancer}\\
\textrm{malignant mesothelioma}\\
\textrm{peripheral nervous system neoplasm}\\
\textrm{autistic disorder}\\
\textrm{meningioma}\\
\textrm{salivary gland cancer}
\end{bmatrix}\]</span>
<p>An adjacency matrix is identical to the information about connections between nodes along a given metanode. Another way to consider an adjacency matrix is that it lists the nodes at which one can arrive in one step from a given start node. In this sense, performing a matrix multiplication with two adjacency matrices gives the nodes at which one can arrive in exactly <em>two</em> steps. Further, an arbitrary number of multiplications can be performed between adjacency matrices corresponding to various metaedges, so long as the dimensionality is appropriate to the matrix multiplication in question. Using this method, we can extract what is known as a path count, or the number of ways to traverse the graph between two nodes. In this way of thinking, an adjacency matrix corresponds to the path count for paths of length one. Using the graph in Figure <a href="#fig:eg_graph">2</a>, we could perform a traversal along the meta-<em>path</em> ‘GaDaG’, and would obtain the following matrix:</p>
<span class="math display">\[\begin{bmatrix}
6 &amp; 1 &amp; 2\\
1 &amp; 3 &amp; 1\\
2 &amp; 1 &amp; 3
\end{bmatrix}\]</span>
<p>Notice that the elements along the main diagonal of the above matrix are not zero. This indiciates that we are accounting for paths in which we traverse from nodes as follows: A -&gt; B -&gt; A. Useful information cannot be gained from looping paths such as these, and they introduce considerable noise in measures of connection between nodes. We therefore wanted to eliminate any usage of path count, and replace it with walk count, where a walk is a type of path which <em>cannot</em> loop backwards on itself. In this example and for paths of length two, this is trivial; we simply subtract the main diagonal, and we have converted from a walk count to a path count. However, this conversion becomes non-trivial when dealing with longer paths and overlapping metanode repeats. My work toward this will be further discussed in the Results section.</p>
<p><strong>Discuss what an adjacency matrix is, that this corresponds to a metaedge, path counts, walk counts, why path is better</strong></p>
<h3 id="computational-tools">Computational tools</h3>
<p>All computational work was done in Python version 3.6. Specifically we used an open-source scientific distribution of Python called Anaconda.</p>
<h4 id="matrices">Matrices</h4>
<p>Python’s notable mathematical and array library, NumPy <span class="citation">[<a href="#ref-eye5ay6P">12</a>]</span>, has an n-dimensional array class called an <code>ndarray</code>. <code>numpy.ndarray</code>s are very useful for representing matrix information, and have superior functionality for our purposes than the native <code>numpy.matrix</code> class. However, as can be seen in Table <a href="#tbl:nodes-by-type">1</a>, the number of nodes in a given adjacency matrix can be upwards of 20,000. In performing matrix multiplications, this can become a computation-intensive process that requires both significant CPU power and memory. Additionally, since the adjacency matrices are full of more zeros than ones, a majority of the multiplications performed are trivial zero multiplications.</p>
<p>One of my early goals for the summer was the conversion of all walk-count (and subsequently, path count) functions to sparse matrices. Sparse matrices, as employed by the Python library SciPy <span class="citation">[<a href="#ref-LsT2mKA3">13</a>]</span>, represent data in matrices which are primarily composed of zeros. The selection of sparse representation and threshold are discussed in the Results section, but sparse matrices warrant a brief description.</p>
<p>In the sparse representation we used, Compressed-sparse-column format (CSC), a matrix is stored as three one-dimensional arrays.</p>
<p>Consider the following matrix:</p>
<span class="math display">\[\begin{bmatrix}
4 &amp; 5 &amp; 0 &amp; 0\\ 
0 &amp; 0 &amp; 1 &amp; 0\\ 
3 &amp; 0 &amp; 0 &amp; 9\\ 
0 &amp; 6 &amp; 0 &amp; 5
\end{bmatrix}\]</span>
<p>We represent the nonzero elements with one array, with the elements being taken from left to right, from top to bottom.</p>
<span class="math display">\[\begin{bmatrix}
4 &amp; 3 &amp; 5 &amp; 6 &amp; 1 &amp; 9 &amp; 5
\end{bmatrix}\]</span>
<p>Next, we give the row indices of these elements.</p>
<span class="math display">\[\begin{bmatrix}
0 &amp; 2 &amp; 0 &amp; 3 &amp; 1 &amp; 2 &amp; 3
\end{bmatrix}\]</span>
<p>The final array represents what is called a column pointer. This array gives the indices where each column starts.</p>
<span class="math display">\[\begin{bmatrix}
0 &amp; 2 &amp; 4 &amp; 5 &amp; 7
\end{bmatrix}\]</span>
<p>These three arrays represent the entirety of a matrix.</p>
<h4 id="other-tools">Other tools</h4>
<p>A significant amount of work done later in the summer involved attempting to compare the new functions to the quite slow old functions. As has become relatively standard for much of computational work, we made use of Jupyter notebooks <span class="citation">[<a href="#ref-klbqKLT4">14</a>]</span> to display the code used to run analysis and its output in a re-usable way. Within this, we were able to effectively incorporate the data manipulation and analysis library pandas <span class="citation">[<a href="#ref-iE9hnE2z">15</a>]</span> and the multiprocessing library concurrent.futures <span class="citation">[<a href="#ref-AwSIzjc6">16</a>]</span>. For visualization, we utilized the online service Neo4j to represent Hetionet v1.0 <span class="citation">[<a href="#ref-cagYjYkt">17</a>]</span>, and the Python graphing library Matplotlib <span class="citation">[<a href="#ref-118qTQ4yr">18</a>]</span>.</p>
<p>The most important tool we used this summer to track progress was the version control software, Git. Our repositories were hosted on the online git hosting service, GitHub <span class="citation">[<a href="#ref-tgH1jNoV">19</a>]</span>. Specifically, every contribution I made this summer can be viewed in detail at my GitHub profile <span class="citation">[<a href="#ref-14DftF1SD">20</a>]</span>. This will be discussed further in the Results section below.</p>
<h2 id="results">Results</h2>
<h2 id="next-steps">Next steps</h2>
<h2 id="citations" class="unnumbered">Citations</h2>
<div id="refs" class="references">
<div id="ref-LlRXV6lE">
<p>1. Scannell JW, Blanckley A, Boldon H, Warrington B. 2012 Diagnosing the decline in pharmaceutical R&amp;D efficiency. <em>Nat Rev Drug Discov</em> <strong>11</strong>, 191–200. See <a href="https://doi.org/10.1038/nrd3681" class="uri">https://doi.org/10.1038/nrd3681</a>.</p>
</div>
<div id="ref-13c9OPizf">
<p>2. DiMasi JA, Grabowski HG, Hansen RW. 2016 Innovation in the pharmaceutical industry: New estimates of R&amp;D costs. <em>Journal of Health Economics</em> <strong>47</strong>, 20–33. See <a href="https://doi.org/10.1016/j.jhealeco.2016.01.012" class="uri">https://doi.org/10.1016/j.jhealeco.2016.01.012</a>.</p>
</div>
<div id="ref-nn9rnuHx">
<p>3. DiMasi JA, Hansen RW, Grabowski HG. 2003 The price of innovation: new estimates of drug development costs. <em>Journal of Health Economics</em> <strong>22</strong>, 151–185. See <a href="https://doi.org/10.1016/s0167-6296(02)00126-1" class="uri">https://doi.org/10.1016/s0167-6296(02)00126-1</a>.</p>
</div>
<div id="ref-269zMv7S">
<p>4. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. 1991 Cost of innovation in the pharmaceutical industry. <em>Journal of Health Economics</em> <strong>10</strong>, 107–142. See <a href="https://doi.org/10.1016/0167-6296(91)90001-4" class="uri">https://doi.org/10.1016/0167-6296(91)90001-4</a>.</p>
</div>
<div id="ref-z38InjRh">
<p>5. Pammolli F, Magazzini L, Riccaboni M. 2011 The productivity crisis in pharmaceutical R&amp;D. <em>Nat Rev Drug Discov</em> <strong>10</strong>, 428–438. See <a href="https://doi.org/10.1038/nrd3405" class="uri">https://doi.org/10.1038/nrd3405</a>.</p>
</div>
<div id="ref-g5JcTYOY">
<p>6. Schuhmacher A, Gassmann O, Hinder M. 2016 Changing R&amp;D models in research-based pharmaceutical companies. <em>J Transl Med</em> <strong>14</strong>, 105. See <a href="https://www.ncbi.nlm.nih.gov/pubmed/27118048" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/27118048</a>.</p>
</div>
<div id="ref-o8yROPbx">
<p>7. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. 2014 Clinical development success rates for investigational drugs. <em>Nat Biotechnol</em> <strong>32</strong>, 40–51. See <a href="https://doi.org/10.1038/nbt.2786" class="uri">https://doi.org/10.1038/nbt.2786</a>.</p>
</div>
<div id="ref-c7z5BwrM">
<p>8. Nosengo N. 2016 Can you teach old drugs new tricks? <em>Nature</em> <strong>534</strong>, 314–316. See <a href="https://doi.org/10.1038/534314a" class="uri">https://doi.org/10.1038/534314a</a>.</p>
</div>
<div id="ref-X1hJHTyw">
<p>9. greenelab. In press. greenelab/hetmech. <em>GitHub</em>. See <a href="https://github.com/greenelab/hetmech" class="uri">https://github.com/greenelab/hetmech</a>.</p>
</div>
<div id="ref-XJuQlZl1">
<p>10. Himmelstein DS, Baranzini SE. 2015 Heterogeneous Network Edge Prediction: A Data Integration Approach to Prioritize Disease-Associated Genes. <em>PLoS Comput Biol</em> <strong>11</strong>, e1004259. See <a href="https://www.ncbi.nlm.nih.gov/pubmed/26158728" class="uri">https://www.ncbi.nlm.nih.gov/pubmed/26158728</a>.</p>
</div>
<div id="ref-w4Mi034s">
<p>11. Weisstein EW. In press. Adjacency Matrix. <em>MathWorld–A Wolfram Web Resource</em>. See <a href="http://mathworld.wolfram.com/AdjacencyMatrix.html" class="uri">http://mathworld.wolfram.com/AdjacencyMatrix.html</a>.</p>
</div>
<div id="ref-eye5ay6P">
<p>12. numpy. In press. numpy/numpy. <em>GitHub</em>. See <a href="https://github.com/numpy/numpy" class="uri">https://github.com/numpy/numpy</a>.</p>
</div>
<div id="ref-LsT2mKA3">
<p>13. scipy. In press. scipy/scipy. <em>GitHub</em>. See <a href="https://github.com/scipy/scipy" class="uri">https://github.com/scipy/scipy</a>.</p>
</div>
<div id="ref-klbqKLT4">
<p>14. jupyter. In press. jupyter/notebook. <em>GitHub</em>. See <a href="https://github.com/jupyter/notebook" class="uri">https://github.com/jupyter/notebook</a>.</p>
</div>
<div id="ref-iE9hnE2z">
<p>15. pandas-dev. In press. pandas-dev/pandas. <em>GitHub</em>. See <a href="https://github.com/pandas-dev/pandas" class="uri">https://github.com/pandas-dev/pandas</a>.</p>
</div>
<div id="ref-AwSIzjc6">
<p>16. 2017 17.4. concurrent.futures — Launching parallel tasks — Python 3.6.2 documentation. See <a href="https://docs.python.org/3/library/concurrent.futures.html" class="uri">https://docs.python.org/3/library/concurrent.futures.html</a>.</p>
</div>
<div id="ref-cagYjYkt">
<p>17. Technology N. 2017 Hetionet · Neo4j Browser. See <a href="https://neo4j.het.io/browser/" class="uri">https://neo4j.het.io/browser/</a>.</p>
</div>
<div id="ref-118qTQ4yr">
<p>18. matplotlib. In press. matplotlib/matplotlib. <em>GitHub</em>. See <a href="https://github.com/matplotlib/matplotlib" class="uri">https://github.com/matplotlib/matplotlib</a>.</p>
</div>
<div id="ref-tgH1jNoV">
<p>19. In press. Greene Laboratory. <em>GitHub</em>. See <a href="https://github.com/greenelab" class="uri">https://github.com/greenelab</a>.</p>
</div>
<div id="ref-14DftF1SD">
<p>20. zietzm. In press. zietzm (Michael Zietz). <em>GitHub</em>. See <a href="https://github.com/zietzm" class="uri">https://github.com/zietzm</a>.</p>
</div>
</div>
<script>
// AnchorJS minified version below.
// Source https://github.com/bryanbraun/anchorjs/blob/064abdd0987f305933ec4982af6d0c1cf2fd0814/anchor.js

/**
 * AnchorJS - v4.0.0 - 2017-06-02
 * https://github.com/bryanbraun/anchorjs
 * Copyright (c) 2017 Bryan Braun; Licensed MIT
 */
!function(A,e){"use strict";"function"==typeof define&&define.amd?define([],e):"object"==typeof module&&module.exports?module.exports=e():(A.AnchorJS=e(),A.anchors=new A.AnchorJS)}(this,function(){"use strict";function A(A){function e(A){A.icon=A.hasOwnProperty("icon")?A.icon:"",A.visible=A.hasOwnProperty("visible")?A.visible:"hover",A.placement=A.hasOwnProperty("placement")?A.placement:"right",A.class=A.hasOwnProperty("class")?A.class:"",A.truncate=A.hasOwnProperty("truncate")?Math.floor(A.truncate):64}function t(A){var e;if("string"==typeof A||A instanceof String)e=[].slice.call(document.querySelectorAll(A));else{if(!(Array.isArray(A)||A instanceof NodeList))throw new Error("The selector provided to AnchorJS was invalid.");e=[].slice.call(A)}return e}function n(){if(null===document.head.querySelector("style.anchorjs")){var A,e=document.createElement("style");e.className="anchorjs",e.appendChild(document.createTextNode("")),void 0===(A=document.head.querySelector('[rel="stylesheet"], style'))?document.head.appendChild(e):document.head.insertBefore(e,A),e.sheet.insertRule(" .anchorjs-link {   opacity: 0;   text-decoration: none;   -webkit-font-smoothing: antialiased;   -moz-osx-font-smoothing: grayscale; }",e.sheet.cssRules.length),e.sheet.insertRule(" *:hover > .anchorjs-link, .anchorjs-link:focus  {   opacity: 1; }",e.sheet.cssRules.length),e.sheet.insertRule(" [data-anchorjs-icon]::after {   content: attr(data-anchorjs-icon); }",e.sheet.cssRules.length),e.sheet.insertRule(' @font-face {   font-family: "anchorjs-icons";   src: url(data:n/a;base64,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) format("truetype"); }',e.sheet.cssRules.length)}}this.options=A||{},this.elements=[],e(this.options),this.isTouchDevice=function(){return!!("ontouchstart"in window||window.DocumentTouch&&document instanceof DocumentTouch)},this.add=function(A){var i,o,s,c,r,a,h,l,u,d,f,g,p=[];if(e(this.options),"touch"===(g=this.options.visible)&&(g=this.isTouchDevice()?"always":"hover"),A||(A="h2, h3, h4, h5, h6"),0===(i=t(A)).length)return this;for(n(),o=document.querySelectorAll("[id]"),s=[].map.call(o,function(A){return A.id}),r=0;r<i.length;r++)if(this.hasAnchorJSLink(i[r]))p.push(r);else{if(i[r].hasAttribute("id"))c=i[r].getAttribute("id");else if(i[r].hasAttribute("data-anchor-id"))c=i[r].getAttribute("data-anchor-id");else{u=l=this.urlify(i[r].textContent),h=0;do{void 0!==a&&(u=l+"-"+h),a=s.indexOf(u),h+=1}while(-1!==a);a=void 0,s.push(u),i[r].setAttribute("id",u),c=u}d=c.replace(/-/g," "),(f=document.createElement("a")).className="anchorjs-link "+this.options.class,f.href="#"+c,f.setAttribute("aria-label","Anchor link for: "+d),f.setAttribute("data-anchorjs-icon",this.options.icon),"always"===g&&(f.style.opacity="1"),""===this.options.icon&&(f.style.font="1em/1 anchorjs-icons","left"===this.options.placement&&(f.style.lineHeight="inherit")),"left"===this.options.placement?(f.style.position="absolute",f.style.marginLeft="-1em",f.style.paddingRight="0.5em",i[r].insertBefore(f,i[r].firstChild)):(f.style.paddingLeft="0.375em",i[r].appendChild(f))}for(r=0;r<p.length;r++)i.splice(p[r]-r,1);return this.elements=this.elements.concat(i),this},this.remove=function(A){for(var e,n,i=t(A),o=0;o<i.length;o++)(n=i[o].querySelector(".anchorjs-link"))&&(-1!==(e=this.elements.indexOf(i[o]))&&this.elements.splice(e,1),i[o].removeChild(n));return this},this.removeAll=function(){this.remove(this.elements)},this.urlify=function(A){var t=/[& +$,:;=?@"#{}|^~[`%!'<>\]\.\/\(\)\*\\]/g;return this.options.truncate||e(this.options),A.trim().replace(/\'/gi,"").replace(t,"-").replace(/-{2,}/g,"-").substring(0,this.options.truncate).replace(/^-+|-+$/gm,"").toLowerCase()},this.hasAnchorJSLink=function(A){var e=A.firstChild&&(" "+A.firstChild.className+" ").indexOf(" anchorjs-link ")>-1,t=A.lastChild&&(" "+A.lastChild.className+" ").indexOf(" anchorjs-link ")>-1;return e||t||!1}}return A});

// Enable links for selected headers
var anchors = new AnchorJS();
anchors.add("h2, h3, h4")
</script>
</body>
</html>
